Applied molecular transport inc
AMTI AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
AMTI Current Performance
5.54%
Applied molecular transport inc
2.31%
Avg of Sector
0.59%
S&P500
Top 10 High Relevance to AMTI
| Symbol | Value | Trend | Swing Trading | Whale Interest | Dividend | Market Cap | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ALVR Allovir inc | 2 | 3 | 2 | 1 | 1 | 224.7M | |
AMYT Amryt pharma plc | - | - | - | - | - | 937M | |
ELTX Angion biomedica corp | - | 1 | 2 | 1 | 1 | 49.5M | |
CCCC C4 therapeutics inc | 4 | 1 | 2 | 1 | 1 | 78.8M | |
CSTL Castle biosciences inc | 4 | 4 | 5 | 3 | 1 | 537.4M |
- ALVR Allovir incValue 2Trend 3Swing Trading 2Whale Interest 1Dividend 1Market Cap 224.7MSee more
AMTI Profile
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company's pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.